Amneal Pharmaceuticals
440 U.S. Highway 22 East
Suite 104
Bridgewater
New Jersey
08807
United States
Tel: 908-947-3120
Fax: 908-947-4146
Website: http://www.amneal.com/
275 articles about Amneal Pharmaceuticals
-
Amneal Reports Second Quarter 2022 Financial Results
8/5/2022
Amneal Pharmaceuticals, Inc. announced its results for the second quarter ended June 30, 2022.
-
Amneal Appoints Deborah M. Autor to Board of Directors
8/3/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Deborah M. Autor has been appointed to the Company’s Board of Directors, effective July 29, 2022.
-
Amneal to Report Second Quarter 2022 Results on August 5, 2022
7/8/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open.
-
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
6/7/2022
Demonstrates increasing company commitment to responsible value creation.
-
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
6/1/2022
Amneal Launches LYVISPAH ® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders.
-
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
5/27/2022
Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company’s Biologics License Application for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®.
-
Amneal to Participate at the 2022 Jefferies Healthcare Conference
5/24/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New York City.
-
Amneal to Participate at Upcoming Investor Conferences in May 2022
5/13/2022
Amneal Pharmaceuticals, Inc. announced that its investor relations or management team will attend the following investor conferences.
-
Amneal Reports First Quarter 2022 Financial Results
5/4/2022
Amneal Pharmaceuticals, Inc. announced its results for the first quarter ended March 31, 2022.
-
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
4/18/2022
Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed.
-
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.
-
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
4/13/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®.
-
Amneal to Report First Quarter 2022 Results on May 4, 2022
4/7/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open.
-
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
3/24/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical trial evaluating the novel investigational extended-release CD/LD formulation, IPX-203, in Parkinson’s disease patients with motor fluctuations, will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, WA.
-
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
3/17/2022
Amneal Pharmaceuticals, Inc. announced it has been awarded a sub-license from the Medicines Patent Pool to manufacture and commercialize a generic version of nirmatrelvir, co-packaged with ritonavir, in 95 low- and middle-income countries.
-
Releuko is expected to launch in the third quarter of 2022 as a treatment for neutropenia, a low white blood cell condition experienced by chemotherapy patients.
-
Amneal Reports Fourth Quarter and Full Year 2021 Financial Results
3/2/2022
Amneal Pharmaceuticals, Inc. announced its results for the fourth quarter and full year ended December 31, 2021.
-
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
3/1/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.
-
Amneal Expands Injectables Portfolio with 4 New Products
2/17/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the approval of four generic injectables products.
-
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
2/4/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open.